257 filings
PRE 14A
ATRA
Atara Biotherapeutics Inc
Preliminary proxy
12 Apr 24
4:15pm
8-K
ATRA
Atara Biotherapeutics Inc
29 Mar 24
Departure of Directors or Certain Officers
4:30pm
10-K
2023 FY
ATRA
Atara Biotherapeutics Inc
Annual report
28 Mar 24
8:40am
8-K
ATRA
Atara Biotherapeutics Inc
28 Mar 24
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
8:35am
8-K
ATRA
Atara Biotherapeutics Inc
23 Feb 24
Departure of Directors or Certain Officers
4:30pm
424B5
cz32n
9 Jan 24
Prospectus supplement for primary offering
4:28pm
8-K
psm1x1232vz63m vzjm2
9 Jan 24
Entry into a Material Definitive Agreement
4:01pm
8-K
x2t5t7ea
8 Jan 24
Cost Associated with Exit or Disposal Activities
8:11am
S-8
qywcqtptijpgkst8 ao4
3 Jan 24
Registration of securities for employees
4:09pm
8-K
boh1q0xu591kb
20 Dec 23
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories
4:30pm
424B3
09pk5rkthdbkxuu1
17 Nov 23
Prospectus supplement
4:31pm
EFFECT
qerg kgojp3mri
14 Nov 23
Notice of effectiveness
12:15am
8-K
bulw9492
8 Nov 23
Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 for Non-Active Progressive Multiple Sclerosis
9:16pm
CORRESP
e1iw sv32rvrsn
8 Nov 23
Correspondence with SEC
12:00am
UPLOAD
8zp1h nwbdnq4fz56y2
6 Nov 23
Letter from SEC
12:00am
8-K
tlwu6d1k
1 Nov 23
Other Events
4:05pm
8-K
iig9mf3 fmxsk
1 Nov 23
Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results
8:35am
8-K
kkxne
19 Sep 23
Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following
6:19pm